54 / 74 · 0:57 · Original AXON film
Orforglipron
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
Non-peptide GLP-1 receptor agonist
Orforglipron shows why a receptor target and a molecule type are different things. It acts at the GLP-1 receptor but is a non-peptide molecule. [1] [2]
US FDA approval | April 2026
In April 2026, FDA approved the tablet product Foundayo for weight management in specified adults, alongside reduced-calorie eating and increased physical activity. [1] [2]
Randomized trials and safety review
The approval relied on two randomized, placebo-controlled trials. Weight reduction was greater with treatment, while gastrointestinal side effects and other warnings remained part of the evaluation. [1] [2]
A product-specific conclusion
The evidence belongs to the reviewed product and indication. Sharing a receptor target does not make drugs interchangeable, and an approved tablet does not validate unrelated research material. [1] [2]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- FDA (2026): Approval of Foundayo, orforglipron →April 1, 2026 approval, adult weight-management indication, two randomized trials, and important safety warnings.
- FDA (2026): Orforglipron multidisciplinary review, NDA 220934 →Non-peptide molecular identity and formulation-specific review.
